Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 20/20 | 0.56 |
| ▸ | ACACA | Q13085 | 17/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13590733 | 0.91 | ACACB (0.54) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4401332 | 0.89 | ACACB (0.72) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4401327 | 0.89 | ACACB (0.72) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4390044 | 0.87 | ACACB (0.51) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4390055 | 0.87 | ACACB (0.51) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4390051 | 0.87 | ACACB (0.51) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4012250 | 0.85 | ACACB (0.55) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4012255 | 0.85 | ACACB (0.55) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13590748 | 0.83 | ACACB (0.64) | ACACBACACACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4014311 | 0.83 | ACACB (0.58) | ACACBACACACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885CYP1A2 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.